EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical prognostic indicators in multiple system atrophy

Yee Yen Goh, Viorica Chelban iD, Nirosen Vijiaratnam, Christine Girges, Manmohan Sandhu, Riona Fumi, Patrick W Cullinane iD, Rahema Mohammad, Michele T Hu iD, James B Rowe, Nicola Pavese iD, Neil Archibald und 6 weitere

Brain · 07.05.2026

DOI: 10.1093/brain/awag160 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 07.05.2026. Verfasst von Yee Yen Goh und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, Queen Square, London, WC1N 3BG, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple system atrophy (MSA) is a neurodegenerative condition causing parkinsonism, cerebellar ataxia and/or dysautonomia. Typical survival is between 6-10 years, but some people die before five or after 15 years. This heterogeneity complicates advanced planning and clinical trial stratification. MSA prognostication studies have shown conflicting results, possibly due to diagnostic accuracy or study size. We report results from a study of survival prognostic factors in a cohort of 555 MSA patients (including the largest post-mortem confirmed cohort to date of 254 people) gathered through the Queen Square Brain Bank and the PROSPECT-M-UK multi-centre prospective cohort study. Through PROSPECT-M-UK, 318 clinically diagnosed MSA patients (17 overlapped with the QSBB cohort) were followed up annually over 5 years. The QSBB cohort clinical data was collected through retrospective review of primary and secondary care documentation. Survival analysis was performed using counting process Cox proportionate hazards modelling, Kaplan-Meier log-rank testing and landmark survival analysis to account for guarantee-time bias. Mean onset age in the combined cohort was 58.7±9.0y with median survival of 8.25y (95% CI:7.88-8.63). 28.8% were clinically diagnosed in-life with MSA-P, 23.8% MSA-C, 40.2% mixed and the rest as non-MSA diagnoses. Later disease onset was associated with shorter survival (HR=1.04, P<0.001). The commonest cause of death was respiratory infection (67%) followed by disease related decline (20%). Median survival from indoor wheelchair use, gastrostomy insertion or development of unintelligible speech was consistently <1.5 years (95% CI upper limits<2.4 years), making these reliable late-stage disease markers. Using landmark analysis, at 3 years from onset, negative prognostic factors included recurrent falls, unintelligible speech, use of catheters and of medication for orthostatic hypotension (HR = 1.57, 3.29, 1.76, 3.29;all P<0.05). At 5 years from onset, mobility milestones including walking aid use, outdoor and indoor wheelchair use (HR = 1.70, 1.93, 2.62;all P<0.01) became significant, whilst dysautonomia milestones (catheter and orthostatic support medication use) were no longer significant. Median individual Unified Multiple System Atrophy Rating Scale (UMSARS) progression rate (n=91) was 10.27 (IQR:5.31-14.30) points/year and did not correlate with symptom duration. Higher baseline UMSARS and faster UMSARS progression were negative prognostic factors of survival from baseline review (HR=1.03 and 1.07 respectively, both P<0.001). We show that in-clinic rating scales and clinical milestone assessment can aid MSA prognostication. Importantly, prognostic factors demonstrate time-dependent variability, which may contribute to previous heterogeneity observed in smaller studies. This knowledge is important for patient care and should inform future clinical trial stratification.

Schlagwörter

Stichwörter der Autor:innen

dysautonomianeurodegenerationparkinsonismprognosisprogressionsurvival

Autor:innen und Institutionen

  • Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, Queen Square, London, WC1N 3BG, UK.
  • Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, UCL, Queen Square, London, WC1N 3BG, UK.
  • UCL Medical School, UCL, Gower Street, London, WC1E 6BT, UK.
  • Queen Square Brain Bank for Neurological Disorders, Queen Square Institute of Neurology, UCL, London, WC1N 3BG, UK.
  • Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, OX3 9DU, UK.
  • Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge CB2 7EF, UK.

ORCID-Profile: Viorica Chelban, Patrick W Cullinane, Michele T Hu, Nicola Pavese, Thomas Foltynie, Huw R Morris, Tom Warner, Henry Houlden

Förderung

  • Wellcome Trust

Zitieren

APA

Goh, Y. Y., Chelban, V., Vijiaratnam, N., Girges, C., Sandhu, M., Fumi, R., Cullinane, P. W., Mohammad, R., Hu, M. T., Rowe, J. B., Pavese, N., Archibald, N., Kobylecki, C., Foltynie, T., Morris, H. R., Warner, T., Jaunmuktane, Z., & Houlden, H. (2026). Clinical prognostic indicators in multiple system atrophy. Brain. https://doi.org/10.1093/brain/awag160

Vancouver

Goh YY, Chelban V, Vijiaratnam N, Girges C, Sandhu M, Fumi R, et al. Clinical prognostic indicators in multiple system atrophy. Brain. 2026. doi:10.1093/brain/awag160

BibTeX
@article{Goh2026,
  author = {Goh, Yee Yen and Chelban, Viorica and Vijiaratnam, Nirosen and Girges, Christine and Sandhu, Manmohan and Fumi, Riona and Cullinane, Patrick W and Mohammad, Rahema and Hu, Michele T and Rowe, James B and Pavese, Nicola and Archibald, Neil and Kobylecki, Christopher and Foltynie, Thomas and Morris, Huw R and Warner, Tom and Jaunmuktane, Zane and Houlden, Henry},
  title = {Clinical prognostic indicators in multiple system atrophy},
  journal = {Brain},
  year = {2026},
  doi = {10.1093/brain/awag160}
}
Kostenlos starten →